Nanomaterials in Personalized Medicine Market Report 2026

The nanomaterials in personalized medicine market size has grown rapidly in recent years. It will grow from $392.97 billion in 2025 to $438.79 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to advancements in genomics and molecular biology, increasing adoption of targeted therapies, expansion of translational medical research, availability of advanced nanofabrication techniques, growth of academic-industry collaborations.

The nanomaterials in personalized medicine market size is expected to see rapid growth in the next few years. It will grow to $674.28 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for personalized healthcare solutions, rising investment in precision medicine programs, expansion of nanomaterials in diagnostics and imaging, growing focus on minimizing therapy side effects, continued innovation in nano-enabled medical technologies. Major trends in the forecast period include increasing use of targeted nanomaterials for individualized therapies, growing integration of molecular diagnostics with nanotechnology, rising adoption of nanomaterials in precision drug delivery, expansion of nanotechnology in regenerative medicine, enhanced focus on patient-specific treatment outcomes.

The increasing demand for personalized medicine is expected to drive the growth of the nanomaterials in personalized medicine market in the coming years. Personalized medicine is a healthcare strategy that emphasizes tailoring treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. This demand is rising due to advancements in genomic technologies, which enable accurate identification of genetic variations and the creation of patient-specific therapies. Nanomaterials in personalized medicine support this approach by allowing targeted, individualized treatments, enhancing both treatment efficacy and safety. They enable precise delivery of drugs, genes, or RNA, reducing side effects and maximizing therapeutic results. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the nanomaterials in personalized medicine market.

The increasing demand for personalized medicine is anticipated to drive the growth of the nanomaterials in personalized medicine market in the coming years. Personalized medicine is a healthcare approach that tailors treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is rising due to advancements in genomic technologies, which enable precise identification of genetic variations and the development of tailored treatments for each individual. Nanomaterials in personalized medicine support this approach by allowing targeted, patient-specific therapies, improving both treatment effectiveness and safety. They enable precise delivery of drugs, genes, or RNA, reducing side effects and maximizing therapeutic benefits. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from 12 approvals in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the nanomaterials in personalized medicine market.

In June 2023, Bayer AG, a Germany-based pharmaceutical and biotechnology company, entered into a partnership with Acuitas Therapeutics Inc. to access its lipid nanoparticle (LNP) delivery technology. This collaboration aims to advance Bayer’s in vivo gene editing and protein replacement programs by leveraging Acuitas’ lipid nanoparticle technology for efficient and targeted RNA delivery, especially to the liver. Acuitas Therapeutics Inc. is a Canada-based biotechnology company specializing in lipid nanoparticle (LNP) delivery systems, which are critical nanomaterials for personalized medicine.

Major companies operating in the nanomaterials in personalized medicine market are Pfizer & Co. Inc., BASF SE, Sanofi S.A., The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA Darmstadt Germany, Evonik Industries AG, Eisai Co. Ltd., TÜV Rheinland AG, OCSiAl S.A., American Elements Inc., Cour Pharmaceuticals Inc., Nanocomposix Inc., NoPo Nanotechnologies Private Limited, Matexcel Biotech Inc., OncoNano Medicine Inc., Molecular Rebar Design Inc., Cello Therapeutics Inc., Apurano Pharmaceuticals GmbH, SGN Nanopharma Inc.

North America was the largest region in the nanomaterials in personalized medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanomaterials in personalized medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanomaterials in personalized medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the nanomaterials in personalized medicine market by increasing costs of imported nanomaterials, surface modification chemicals, analytical instruments, and fabrication equipment used in precision medical applications. Research institutions and pharmaceutical developers in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces cost pressure on nanomaterial exports. These tariffs are raising development costs and extending research timelines. However, they are also promoting domestic nanomaterial synthesis, regional supply chain development, and investment in local advanced materials manufacturing.

The nanomaterials in personalized medicine market research report is one of a series of new reports that provides nanomaterials in personalized medicine market statistics, including nanomaterials in personalized medicine industry global market size, regional shares, competitors with a nanomaterials in personalized medicine market share, detailed nanomaterials in personalized medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nanomaterials in personalized medicine industry. This nanomaterials in personalized medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanomaterials in personalized medicine are specially designed materials at the nanoscale, developed to engage with biological systems in a precise and controlled manner, allowing healthcare interventions to be tailored to an individual’s specific genetic, molecular, or physiological characteristics. These nanomaterials improve therapeutic efficacy while minimizing potential side effects and enhancing overall patient outcomes by enabling targeted, controlled, and personalized medical therapies.

The main categories of nanomaterials in personalized medicine include carbon-based nanomaterials, metallic nanoparticles, polymeric nanomaterials, nanostructured materials, and silica nanoparticles. Carbon-based nanomaterials are extremely small structures mainly composed of carbon, such as graphene, carbon nanotubes, and fullerenes. They consist of various formulation types, including nanoparticles, nanosuspensions, nanoemulsions, nanocrystals, and nanoformulations for targeted delivery, and utilize technologies like nanofabrication techniques, bioconjugation methods, surface modification techniques, molecular imaging techniques, and nanotechnology-based screening methods. Their applications span drug delivery systems, diagnostics and imaging, therapeutics, regenerative medicine, vaccines, and they serve a wide array of end users, including hospitals and clinics, research laboratories, pharmaceutical companies, biotechnology firms, and academic institutions.

The nanomaterials in personalized medicine market consists of revenues earned by entities by providing services such as gene and RNA therapy formulation, personalized diagnostic solutions, nanocarrier design and manufacturing, clinical translation support, and custom nanoparticle-based treatment development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanomaterials in personalized medicine market also includes sales of targeted gene delivery kits, nanoparticle-based diagnostic kits, nanocarrier-enabled vaccine formulations, nano-biosensors, and lab-scale nanofabrication equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.